AstraZeneca and Karolinska Institutet: a new industry-academia partnership model

AstraZeneca has collaborated with Karolinska Institutet in Sweden, one of the world’s leading medical research universities, for many years on different projects.

In 2013, we created a joint centre for research on cardiovascular and metabolic diseases. This goes deeper than the usual industry-academia partnership, as scientists from both partners work side-by-side in a dedicated university unit to develop new therapies for people in need. The Integrated Cardio Metabolic Centre (ICMC) aims to identify and validate novel targets within cardiometabolic diseases, focusing on three strategic research areas: heart failure, diabetes and chronic kidney disease across both small molecules and biologics.